Search results for Kuros Biosciences

Latest updates for Kuros Biosciences

Fresh curated links around Kuros Biosciences are collected here so marketers can spot useful updates and turn timely ideas into posts faster.

Post angles to try

Share the most useful takeaway for your audience.

Turn one article into a quick practical checklist.

Ask your audience how this shift affects their work.

Turn angles into scheduled posts

Fresh articles and ideas

Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.

ryortho.com /3 weeks ago

Kuros Biosciences appoints I.V. Hall as Chief Operating Officer, deepening operational, R&D and extremities leadersh...

Read source

fiercebiotech.com /1 month ago

Alzheimer's-focused Korsana to use Cyclerion reverse merger to go public

After emerging from stealth last month with $175 million in funding, Korsana Biosciences has wasted no time making its way to the public markets.

Read source

orthospinenews.com /3 weeks ago

Kuros Biosciences appoints I.V. Hall as Chief Operating Officer, deepening operational, R&D and extremities leadersh...

Kuros Biosciences appoints I.V. Hall as Chief Operating Officer, deepening operational, R&D and extremities leadership for next phase of…

Read source

fiercebiotech.com /4 days ago

Kura posts Krazati combo data on drug designed to unleash KRAS inhibitors’ potential

Kura Oncology has published early data on darlifarnib in combination with Bristol Myers Squibb’s Krazati, linking the drug candidate to response rates of up to 69% when given with...

Read source

seekingalpha.com /1 month ago

Kura Oncology: Commercialization In AML Presents Asymmetric Upside

Read source

newswire.com /2 weeks ago

Ensysce Biosciences Reports First Quarter 2026 Financial Results

~ IRB Approval Secured for PF614-MPAR-102 Part 3 ~~ Clinical Peer-Reviewed Data Published for First Overdose Protected Opioid PF614-MPAR®; Patent Estate Expanded ~~ Company Launche...

Read source

newswire.com /1 month ago

Ensysce Biosciences Secures IRB Approval of Final Phase of PF614-MPAR-102 Clinical Study

~ Advances First-in-Class Opioid with Oral Overdose-Protection ~

Read source

qchron.com /2 weeks ago

Kelun-Biotech Receives Investigational New Drug Approval from CDE for SKB118, a PD-1 x VEGF Bispecific Antibody

CHENGDU, China, May 12, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that it has received a clinical...

Read source

cafepharma.com /5 days ago

Beigene

Beigene Anonymous (not verified) Mon, 05/25/2026 - 11:38 field_thread_url https://cafepharma.com/boards/threads/beigene.637588/ board na...

Read source

cafepharma.com /1 month ago

Beigene

Beigene Anonymous (not verified) Thu, 04/30/2026 - 14:18 field_thread_url https://cafepharma.com/boards/threads/beigene.637588/ board na...

Read source

cafepharma.com /2 weeks ago

BridgeBio

BridgeBio Anonymous (not verified) Mon, 05/11/2026 - 11:23 field_thread_url https://cafepharma.com/boards/threads/bridgebio.698762/ boar...

Read source

seekingalpha.com /2 weeks ago

KYORIN Pharmaceutical Co., Ltd. 2026 Q4 - Results - Earnings Call Presentation

Read source

cafepharma.com /3 weeks ago

Revolution Medicines

Revolution Medicines Anonymous (not verified) Tue, 05/05/2026 - 02:20 field_thread_url https://cafepharma.com/boards/threads/revolution-medicines.709803/...

Read source

fiercebiotech.com /1 month ago

Australia’s Kazia pays research institute $1.4M for epigenetic platform, preclinical drug

Kazia Therapeutics is paying $1.4 million upfront to secure a platform for generating epigenetic drugs from an Australian research institute.

Read source

biopharmadive.com /3 days ago

Cardio drugmaker Kardigan plans to go public

Founded by former MyoKardia executives, the startup has in mid- to late-stage testing three medicines licensed from the likes of Sanofi, Ionis and Bristol Myers Squibb.

Read source

seekingalpha.com /1 month ago

Kura Oncology, Inc. (KURA) Discusses Updated Data on Darlifarnib and Cabozantinib Combination in Advanced Renal Cell Car...

Read source

pharmexec.com /3 weeks ago

<![CDATA[UCB Enters $2.2 Billion Agreement to Acquire Candid Therapeutics ]]>

Read source

pharmexec.com /1 month ago

<![CDATA[Gilead Enters $5 Billion Agreement to Acquire Tubulis ]]>

Read source

fiercebiotech.com /2 weeks ago

Transforming neurodegenerative disease treatment

Discover how Cognition Therapeutics is redefining hope for Alzheimer’s and Dementia with Lewy bodies [JG1] with innovative, accessible therapies.

Read source

fiercebiotech.com /2 weeks ago

NeuroVision acquires fellow dx player Durin Life Sciences

NeuroVision, which is working toward regulatory approval for its early Alzheimer’s detection technology, acquired fellow diagnostics maker Durin Life Sciences for an undisclosed pr...

Read source

cafepharma.com /1 week ago

Kiniksa

Kiniksa Anonymous (not verified) Tue, 05/19/2026 - 08:34 field_thread_url https://cafepharma.com/boards/threads/kiniksa.658756/ board na...

Read source

qchron.com /1 month ago

CGBIO Showcases Comprehensive Medical Device Portfolio at KIMES 2026 Achieves KRW 5.3 Billion in Contract Results

- Presented key product lines spanning aesthetic, wound care, bone and spine, and surgical fields

Read source

biopharmadive.com /1 month ago

Kailera nets $625M in one of biotech’s biggest-ever IPOs

The high-profile obesity drug developer priced the biotech sector’s biggest offering in years and will use the proceeds to support a portfolio of medicines licensed from China’s He...

Read source

medcitynews.com /1 month ago

VC Firm Kurma Partners Closes €215M Fund in Pursuit of ‘Disruptive Therapeutic Solutions’

Kurma Partners’ new fund is the venture capital firm’s fourth and largest. Previous Kurma investments have led to exits that include the acquisitions of Corlieve Therapeutics, Emer...

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.